Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy

被引:0
|
作者
Hartrampf, Philipp E. [1 ]
Mihatsch, Patrick W. [2 ]
Seitz, Anna Katharina [3 ]
Solnes, Lilja B. [4 ]
Rowe, Steven P. [4 ]
Pomper, Martin G. [4 ]
Kuebler, Hubert [3 ]
Bley, Thorsten A. [2 ]
Buck, Andreas K. [1 ]
Werner, Rudolf A. [1 ,4 ]
机构
[1] Univ Hosp Wurzburg, Dept Nucl Med, Wurzburg, Germany
[2] Univ Hosp Wurzburg, Dept Diagnost & Intervent Radiol, Wurzburg, Germany
[3] Univ Hosp Wurzburg, Dept Urol & Paediat Urol, Wurzburg, Germany
[4] Johns Hopkins Univ, Russell H Morgan Dept Radiol & Radiol Sci, Sch Med, Baltimore, MD USA
关键词
PSMA; prostate cancer; radioligand therapy; overall survival; body composition; ANDROGEN-DEPRIVATION THERAPY; CLINICAL-OUTCOMES; OPEN-LABEL; MEN; FAT; CHEMOTHERAPY; MITOXANTRONE; CABAZITAXEL; ABIRATERONE; PREDNISONE;
D O I
10.2967/jnumed.122.265379
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
In patients with prostate cancer scheduled for systemic treatment, being overweight is linked to prolonged overall survival (OS), whereas sarcopenia is associated with shorter OS. We investigated fat-related and body composition parameters in patients undergoing prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) to assess their predictive value for OS. Methods: Body mass index (BMI, in kg/m(2)) and CT-derived body composition parameters (total, subcutaneous, visceral fat area, and psoas muscle area at the L3-L4 level) were determined for 171 patients scheduled for PSMA-directed RLT. After normalization for stature, the psoas muscle index was used to define sarcopenia. Outcome analysis was performed using Kaplan-Meier curves and Cox regression including fat-related and other clinical parameters (Gleason score, C-reactive protein [CRP], lactate dehydrogenase [LDH], hemoglobin, and prostate-specific antigen levels). The Harrell C-index was used for goodness-of-fit analysis. Results: Sixty-five patients (38%) had sarcopenia, and 98 patients (57.3%) had increased BMI. Relative to the 8-mo OS in normal-weight men (BMI < 25), overweight men (25 = BMI > 30) and obese men (BMI =30) achieved a longer OS of 14 mo (hazard ratio [HR], 0.63; 95% CI, 0.40-0.99; P = 0.03) and 13 mo (HR, 0.47; 95% CI, 0.29-0.77; P = 0.004), respectively. Sarcopenia showed no impact on OS (11 vs. 12 mo; HR, 1.4; 95% CI, 0.91-2.1; P = 0.09). Most of the body composition parameters were tightly linked to OS on univari-able analyses, with the highest C-index for BMI. In multivariable analy-sis, a higher BMI (HR, 0.91; 95% CI, 0.86-0.97; P = 0.006), lower CRP (HR, 1.09; 95% CI, 1.03-1.14; P < 0.001), lower LDH (HR, 1.08; 95% CI, 1.03-1.14; P < 0.001), and longer interval between initial diagnosis and RLT (HR, 0.95; 95% CI, 0.91-0.99; P = 0.02) were significant pre-dictors of OS. Conclusion: Increased fat reserves assessed by BMI, CRP, LDH, and interval between initial diagnosis and RLT, but not CT-derived body composition parameters, were relevant predictors for OS. As BMI can be altered, future research should investigate whether a high-calorie diet before or during PSMA RLT may improve OS.
引用
收藏
页码:1272 / 1278
页数:7
相关论文
共 50 条
  • [41] The change in expression of prostate-specific membrane antigen in circulating tumor cells during treatments for castration-resistant prostate cancer
    Nagaya, N.
    Kanayama, M.
    Nagata, M.
    Horie, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] Expression of prostate-specific membrane antigen (PSMA) on circulating tumor cells (CTCs) in castration-resistant prostate cancer.
    Lee, Florence
    Yu, Angela
    Anderson, Amanda
    Marrinucci, Dena
    Magargal, Wells W.
    DiPippo, Vincent A.
    Olson, William C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [43] Re: Prostate-specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-resistant Prostate Cancer
    Walz, Jochen
    EUROPEAN UROLOGY, 2020, 78 (02) : 292 - 293
  • [44] Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy
    Sue Ping Thang
    Violet, John
    Sandhu, Shahneen
    Iravani, Amir
    Akhurst, Tim
    Kong, Grace
    Kumar, Aravind Ravi
    Murphy, Declan G.
    Williams, Scott G.
    Hicks, Rodney J.
    Hofman, Michael S.
    EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (06): : 670 - 676
  • [45] Description of FDG and Prostate-Specific Membrane Antigen PET/CT Findings in Korean Patients With Advanced Metastatic Castration-Resistant Prostate Cancer
    Na, Sae Jung
    Ha, Seunggyun
    Kim, In-Ho
    Lee, Ji Youl
    O, Joo Hyun
    KOREAN JOURNAL OF RADIOLOGY, 2024, 25 (11) : 1022 - 1028
  • [46] Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy A Systematic Review and Meta-analysis
    Satapathy, Swayamjeet
    Mittal, Bhagwant Rai
    Sood, Ashwani
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (12) : 935 - 942
  • [47] Prognostic Value of Body Mass Index in Korean Patients with Castration-Resistant Prostate Cancer
    Park, Jeong Min
    Nam, Jung Soo
    Na, Woong
    Oh, Jong Jin
    Lee, Sangchul
    Hong, Sung Kyu
    Byun, Seok-Soo
    Lee, Sang Eun
    KOREAN JOURNAL OF UROLOGY, 2012, 53 (11) : 761 - 765
  • [49] Patients with rapid decreasing of prostate-specific antigen in the initial androgen deprivation therapy are more likely to progress to castration-resistant prostate cancer
    Ji, G.
    INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 : 101 - 101
  • [50] Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer
    Hah, Yoon Soo
    Lee, Jong Soo
    Rha, Koon Ho
    Hong, Sung Joon
    Ha Chung, Byung
    Koo, Kyo Chul
    SCIENTIFIC REPORTS, 2019, 9 (1)